Hemoglobin

NovelMed Commences Phase II Trial for Anti-Bb Antibody (NM8074) in Treatment-Naïve PNH Patients: A Glimpse into the PNH Study Progress

Retrieved on: 
Monday, October 30, 2023
FDA, CP, PNH, Hemolysis, C3b, LDH, Intravascular hemolysis, Phase, Phase II, EVH, Lactate dehydrogenase, RBC, Risk, Paroxysmal nocturnal hemoglobinuria, AP, Safety, IVH, Therapy, Patient, Infection, PRBC, Pharmaceutical industry, Haptoglobin, Hemoglobin, Reticulocyte

Regulatory approval for the Phase II trial in treatment-naïve PNH patients was granted based on the safety and tolerance demonstrated in the previous Phase I clinical trial involving healthy subjects.

Key Points: 
  • Regulatory approval for the Phase II trial in treatment-naïve PNH patients was granted based on the safety and tolerance demonstrated in the previous Phase I clinical trial involving healthy subjects.
  • CLEVELAND, Oct. 30, 2023 (GLOBE NEWSWIRE) -- NovelMed Therapeutics is excited to announce the commencement of its Phase II clinical trial targeting treatment-naïve Paroxysmal Nocturnal Hemoglobinuria (PNH) patients with its groundbreaking anti-Bb antibody, NM8074.
  • This open-label, multi-dose, and multi-center study aims to assess the safety and efficacy of NM8074 in PNH patient population.
  • The Phase II study is divided into two cohorts, featuring a biweekly dosing schedule spanning a 3-month assessment period.

Comprehensive Report Highlights Key Market Players, Technologies, and Geographical Segments of Hemoglobin A1c Testing Devices & Kits - ResearchAndMarkets.com

Retrieved on: 
Friday, September 29, 2023
Diabetes, Health, Medical Supplies, Medical Devices, Biomedical technology, Hemoglobin, ESG, Compound annual growth rate, Fine chemical, Marketing, Social

The report provides an overview of the global market landscape related to Hemoglobin A1c Testing Devices & Kits.

Key Points: 
  • The report provides an overview of the global market landscape related to Hemoglobin A1c Testing Devices & Kits.
  • The current market size and revenue growth prospects specific to Hemoglobin A1c Testing Devices & Kits are evaluated, along with a comprehensive market share analysis categorized by technology, end user, and geographical region.
  • The report explores the upcoming market potential for Hemoglobin A1c test devices and kits, and areas of focus to forecast this market into various segments and sub-segments.
  • The role and importance of Environmental, Social, and Governance (ESG) in the Hemoglobin A1c Testing Devices & Kits market are discussed, including consumer attitudes, risks, opportunity assessment, and ESG practices in the industry.

Trinity Biotech plc to Announce Second Quarter Fiscal Year 2023 Financial Results

Retrieved on: 
Wednesday, September 27, 2023
Disease, Glycated hemoglobin, Serum, Coronavirus, COVID-19, Research, Infection, Hemoglobin, Chemistry, Plasma, Regulation of tobacco by the U.S. Food and Drug Administration, Food

Certain statements made in this release that are not historical are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

Key Points: 
  • Certain statements made in this release that are not historical are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
  • The words “estimate”, “project”, “intend”, “expect”, “believe” and similar expressions are intended to identify forward-looking statements.
  • Trinity Biotech develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market.
  • Trinity Biotech sells direct in the United States, Germany, France and the U.K. and through a network of international distributors and strategic partners in over 75 countries worldwide.

Trinity Biotech plc to Announce First Quarter Fiscal Year 2023 Financial Results

Retrieved on: 
Monday, July 3, 2023
Disease, Glycated hemoglobin, Serum, Coronavirus, COVID-19, Research, Infection, Hemoglobin, Chemistry, Plasma, Regulation of tobacco by the U.S. Food and Drug Administration, Food

Certain statements made in this release that are not historical are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

Key Points: 
  • Certain statements made in this release that are not historical are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
  • The words “estimate”, “project”, “intend”, “expect”, “believe” and similar expressions are intended to identify forward-looking statements.
  • Trinity Biotech develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market.
  • Trinity Biotech sells direct in the United States, Germany, France and the U.K. and through a network of international distributors and strategic partners in over 75 countries worldwide.

Omeros Corporation Reports Interim Data with Alternative Pathway Inhibitor OMS906 as Monotherapy in Patients with Paroxysmal Nocturnal Hemoglobinuria

Retrieved on: 
Tuesday, April 25, 2023
Health, Clinical Trials, General Health, Research, Pharmaceutical, Science, Myelodysplastic syndrome, Omeros, Hemolysis, Paroxysmal nocturnal hemoglobinuria, Half-life, AMD, Hemoglobin, Aplastic anemia, Clinical trial, LDH, Geographic atrophy, Multimedia, Disorder, Corporation, HGB, Iron deficiency, Patient, Physician, Risk, PNH, Hematology, Aristotle University of Thessaloniki, Observation, Kidney disease, Disease, Pharmaceutical industry, Surveying, C3

To date, all patients have received only the lowest subcutaneous dose of OMS906 in this multidose trial.

Key Points: 
  • To date, all patients have received only the lowest subcutaneous dose of OMS906 in this multidose trial.
  • This single-arm, open-label clinical trial is evaluating the effect of once-monthly subcutaneous administration of OMS906 in patients with PNH.
  • OMS906 is Omeros’ lead investigational humanized monoclonal antibody targeting MASP-3, the key and most upstream activator of the alternative pathway of complement.
  • “We are excited by the data resulting from this trial of treatment-naïve patients,” said Gregory A. Demopulos, M.D., Omeros’ chairman and chief executive officer.

Trinity Biotech plc to Announce Fourth Quarter and Fiscal Year 2022 Financial Results

Retrieved on: 
Thursday, March 16, 2023
Research, Chemistry, Plasma, Serum, Regulation of tobacco by the U.S. Food and Drug Administration, Coronavirus, Glycated hemoglobin, Disease, COVID-19, Hemoglobin, Infection, Food

Certain statements made in this release that are not historical are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

Key Points: 
  • Certain statements made in this release that are not historical are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
  • The words “estimate”, “project”, “intend”, “expect”, “believe” and similar expressions are intended to identify forward-looking statements.
  • Trinity Biotech develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market.
  • Trinity Biotech sells direct in the United States, Germany, France and the U.K. and through a network of international distributors and strategic partners in over 75 countries worldwide.

Hurdle Launches HbA1c Home Test for Early Detection of Diabetes in Adults

Retrieved on: 
Wednesday, February 1, 2023
Chronobiology, Exploration Flight Test-1, Diabetes, Glycated hemoglobin, Patient, Hemoglobin, Partnership, Pharmaceutical industry

The new test enables adult consumers to take a simple at-home blood sample to screen and monitor for diabetes.

Key Points: 
  • The new test enables adult consumers to take a simple at-home blood sample to screen and monitor for diabetes.
  • Over 8.5 million American adults have undiagnosed diabetes, representing 23 percent of the total diabetes population.
  • The new test will alleviate this burden for patients by giving them a convenient option for screening diabetes.
  • The test is available for purchase today on the Chronomics brand online store for $69.

Trinity Biotech to participate in the Piper Sandler 34th Annual Healthcare Conference

Retrieved on: 
Wednesday, November 30, 2022
COVID-19, Piper Sandler Companies, Disease, Food, Serum, Chemistry, Conference, Regulation of tobacco by the U.S. Food and Drug Administration, Infection, Hemoglobin, Research, Coronavirus, Plasma

DUBLIN, Ireland, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Trinity Biotech (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, is scheduled to participate in the Piper Sandler 34th Annual Healthcare Conference on Thursday, December 1, 2022.

Key Points: 
  • DUBLIN, Ireland, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Trinity Biotech (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, is scheduled to participate in the Piper Sandler 34th Annual Healthcare Conference on Thursday, December 1, 2022.
  • The products are used to detect infectious diseases and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood.
  • Trinity Biotech sells direct in the United States, Germany, France and the U.K. and through a network of international distributors and strategic partners in over 75 countries worldwide.
  • The words estimate, project, intend, expect, believe and similar expressions are intended to identify forward-looking statements.

Trinity Biotech plc to Announce Second Quarter Fiscal Year 2022 Financial Results

Retrieved on: 
Tuesday, November 1, 2022
Plasma, Infection, Research, U.S. Securities and Exchange Commission, Hemoglobin, COVID-19, Chemistry, Regulation of tobacco by the U.S. Food and Drug Administration, Coronavirus, Disease, Private Securities Litigation Reform Act, Company, Serum, Food, Glycated hemoglobin

Certain statements made in this release that are not historical are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

Key Points: 
  • Certain statements made in this release that are not historical are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
  • The words estimate, project, intend, expect, believe and similar expressions are intended to identify forward-looking statements.
  • Trinity Biotech develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market.
  • Trinity Biotech sells direct in the United States, Germany, France and the U.K. and through a network of international distributors and strategic partners in over 75 countries worldwide.